Lenskart Shares Closed Nearly 1% Higher Despite SoftBank Sells 1.56% Stake; Alivus Shares Closed Down After Promoter Offloads Shares

Two significant block transactions took place in Lenskart Solutions Limited and Alivus Life Sciences Limited (formerly Glenmark Life Sciences) on 6 November 2026. SoftBank Group sold a 1.56% stake in Lenskart, while Alivus promoter Nirma reduced its holding in the company. The transactions attracted domestic and international institutional investors.

SoftBank’s affiliate, SVF II Lightbulb (Cayman), sold 2.72 crore Lenskart shares at ₹697.15 apiece. The transaction was valued at ₹1,896.2 crore and represented part of SoftBank’s 7.27% holding, according to the latest shareholding pattern. Thirteen domestic and global institutional investors bought all the shares offloaded.

On 6 November 2026, the Lenskart share price closed at ₹724.75, up 0.89% on the National Stock Exchange (NSE). In contrast, the Alivus Life Sciences share price closed 1.11% down at ₹1,480.60 on the exchange.

Goldman Sachs Leads Institutional Buying

Goldman Sachs acquired 91.84 lakh Lenskart shares worth ₹640.26 crore, making it the largest buyer. Societe Generale ODI followed with 89.44 lakh shares valued at ₹623.53 crore. William Blair Investment Management purchased 11.1 lakh shares worth ₹77.43 crore through seven of its schemes.

Other buyers included:

• Kotak Mahindra Mutual Fund

• Norges Bank

• UTI AMC

• Public School Teachers Pension and Retirement Fund of Chicago

• Florida Retirement System

• The Northern Trust Co.

• Texas Municipal Retirement System

• BNP Paribas Financial Markets

• HDFC Standard Life Insurance Company

• NRSGVCC

Alivus Life Sciences Block Deal

Promoter Nirma sold 28.46 lakh Alivus Life Sciences shares, representing 2.31% of its paid-up equity, for ₹389.94 crore. The transaction took place at ₹1,370 per share and involved seven investors.

Bandhan Mutual Fund was the largest buyer, acquiring 8.55 lakh shares worth ₹117.26 crore. Param Capital purchased 7.29 lakh shares for ₹99.97 crore. Norges Bank, Helios Mutual Fund, Subhkam Ventures I, Sanshi Fund-I and Setu Securities were among the other buyers.

Separately, Nirma sold another 8.33 lakh Alivus Life Sciences shares for ₹118.57 crore at ₹1,422.29 apiece.

Source

NSE - Lenskart NSE - Alivus

Also Read - Siemens Q2 FY27 Results: Revenue Rises 17% To ₹5,734 Crore As New Orders Jump 37.8% To ₹6,228 Crore